# Efficacy and Safety of Intracoronary Ad5FGF-4 in Patients With Stable Angina (AGENT-3)

> **NCT00346437** · PHASE2,PHASE3 · COMPLETED · sponsor: **Cardium Therapeutics** · enrollment: 416 (actual)

## Conditions studied

- Angina Pectoris

## Interventions

- **GENETIC:** Ad5FGF-4 vs. Placebo

## Key facts

- **NCT ID:** NCT00346437
- **Lead sponsor:** Cardium Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-10
- **Primary completion:** 2005-01
- **Final completion:** 2008-11
- **Target enrollment:** 416 (ACTUAL)
- **Last updated:** 2012-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00346437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00346437, "Efficacy and Safety of Intracoronary Ad5FGF-4 in Patients With Stable Angina (AGENT-3)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00346437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*